MedPath

Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease

Completed
Conditions
Sickle Cell Disease
Interventions
Other: Cardiac echography
Other: Biological parameters
Other: Clinical parameters
Registration Number
NCT02394431
Lead Sponsor
Brugmann University Hospital
Brief Summary

Sickle Cell Disease is a serious disease that is life-threatening for patients being homozygous for the SS form or heterozygous for the SC or βthal forms. The CHU Brugmann hospital currently regularly treats about 70 homozygous adult patients and this number is in constant augmentation.

Sickle cell disease patients may develop a cardiomyopathy due to chronic anemia, the haemosiderosis risk or, less frequently, to coronary vaso-occlusive damages.

The hypervolemia in patients with sickle cell disease causes an overestimation of the ejected left ventricular fraction measured by echocardiography, this parameter being very dependent of the blood volume.It has already been shown that the left ventricular ejection fraction was normal in most patients with sickle cell disease, but that its evaluation by parameters independent from the blood volume showed the existence of a dysfunction.

Myocardial strain, as measured by speckle tracking, is a echographic evaluation method of the cardiac function, independent of the blood volume. This technique hasn't been used much in sickle cell disease patients. A study using 3D speckle tracking on a limited number of sickle cell disease patients failed to show a strain anomaly. Moreover, the study highlighted a higher global longitudinal strain in this patient population. The investigators find these data hard to explain and in contradiction with previous studies using other cardiac function evaluation techniques, independent from the blood volume.

The primary goal of this study is thus

* to study the longitudinal strain by 2D echography

* to determine if anomalies of the longitudinal strain exist in sickle cell disease patients with a normal ejected left ventricular fraction, compared to a control group of healthy patients.

The secondary goal of this study is to correlate, inside the sickle cell disease group, the possible strain anomalies with biological gravity parameters of the disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria
  • All sickle cell disease patients
Exclusion Criteria
  • Insufficient echogenicity

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Sickle cell disease patientsCardiac echographySickle cell disease patients
Sickle cell disease patientsBiological parametersSickle cell disease patients
Sickle cell disease patientsClinical parametersSickle cell disease patients
Healthy patientsCardiac echographyThis is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
Healthy patientsBiological parametersThis is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
Primary Outcome Measures
NameTimeMethod
Myocardiac performance indexonce per year, at the annual medical visit planned according to the standart of care for this pathology
Cardiac diastolic functiononce per year, at the annual medical visit planned according to the standart of care for this pathology
Cardiac tissular doppleronce per year, at the annual medical visit planned according to the standart of care for this pathology
Cardiac ejection fractiononce per year, at the annual medical visit planned according to the standart of care for this pathology

Ejection fraction measured by Teicholz and planimety.

Global longitudinal strainonce per year, at the annual medical visit planned according to the standart of care for this pathology

Global longitudinal strain measured by speckle tracking.

arterial pulmonary hypertensiononce per year, at the annual medical visit planned according to the standart of care for this pathology
left ventricular hypertrophyonce per year, at the annual medical visit planned according to the standart of care for this pathology
Secondary Outcome Measures
NameTimeMethod
Biological parameters: hemoglobin levelsonce per year, at the annual medical visit planned according to the standart of care for this pathology
Biological parameters: iron levelsonce per year, at the annual medical visit planned according to the standart of care for this pathology
Biological parameters: hematocrit levelsonce per year, at the annual medical visit planned according to the standart of care for this pathology
Biological parameters: ferritin levelsonce per year, at the annual medical visit planned according to the standart of care for this pathology
Clinical parameters: sanguine transfusion numbersonce per year, at the annual medical visit planned according to the standart of care for this pathology
Clinical parameters: severity of the illnessonce per year, at the annual medical visit planned according to the standart of care for this pathology

Sickle cell disease organ damages.

Biological parameters: red cells countonce per year, at the annual medical visit planned according to the standart of care for this pathology

Trial Locations

Locations (1)

CHU Brugmann

🇧🇪

Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath